|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.95 USD | +17.66% |
|
-34.03% | -96.50% |
| Apr. 19 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
| Apr. 19 | Top Premarket Decliners | MT |
Sunshine Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 4.89 million compared to USD 0.122645 million a year ago. Net loss was USD 1.7 million compared to USD 1.24 million a year ago.
Basic loss per share from continuing operations was USD 8 compared to USD 23 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -96.50% | 854K | |
| +26.47% | 664B | |
| +26.74% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +13.43% | 234B | |
| +4.71% | 199B | |
| -9.53% | 196B | |
| -4.04% | 148B |
SUNSHINE BIOPHARMA, INC. 
